MedTrace Logo

Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy

NCT04273737 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2022-05-31

Study results available
· View outcomes & findings →

Summary

Cerebral palsy (CP) is a common childhood-onset disability associated with motor and cognitive impairments, however most research is focused on motor outcomes. The aim of this study is to determine the effects of Amantadine, a dopaminergic agonist, on cognitive function in adolescents and adults with CP.

Conditions

  • Cerebral Palsy

Interventions

DRUG

Amantadine Hydrochloride

6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.

Sponsors & Collaborators

Principal Investigators

  • Heakyung Kim, MD · Columbia Irving Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2022-02-22
Completion
2022-02-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04273737 on ClinicalTrials.gov